Advertisement

Topics

Seattle Genetics stops Phase III trial of leukaemia drug due to high death rate

19:00 EDT 19 Jun 2017 | Net Resources International

Biotechnology firm Seattle Genetics has stopped the Phase III CASCADE clinical trial of vadastuximab talirine (SGN-CD33A) in older patients with frontline acute myeloid leukaemia (AML).

Original Article: Seattle Genetics stops Phase III trial of leukaemia drug due to high death rate

NEXT ARTICLE

More From BioPortfolio on "Seattle Genetics stops Phase III trial of leukaemia drug due to high death rate"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...